Antibody drug conjugates (ADCs) that link monoclonal antibodies to deliver highly potent active pharmaceutical ingredients (HPAPIs) are inherently complex, making it imperative that you characterize your biotherapy to confirm its structure, binding, purity, and potency. As your characterization partner, we can provide expert guidance on the biological components of your ADC in both its “naked” and drug-conjugated versions – conducting safer, more reliable, and faster testing that helps to expedite product quality decisions at critical junctures.
Our ADC product characterization services feature:
The safety and effectiveness of your ADC starts with understanding the role played by the antibody in directing an ADC to tumor cells, as well as the potential for immune recruitment. Our broad range of assays for conjugated and unconjugated forms can help identify a variety of critical factors:
See standard assay recommendations that can reveal your ADC’s structure, binding, and potency.
To help you bring safe new treatments to market, Merck’s BioReliance® Testing Services offers a broad portfolio of biotherapy characterization, safety testing, and process development, through every step of development, from drug discovery to market approval. Our experienced teams paired with our operational expertise and deep regulatory understanding help you minimize risk at every step of your process.